已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Real-world outcomes of intrapleural platinum-based chemotherapy in lung cancer patients with symptomatic malignant pleural effusion: A multicenter cohort study

医学 肺癌 恶性胸腔积液 危险系数 化疗 内科学 临床终点 置信区间 外科 胸腔积液 回顾性队列研究 比例危险模型 倾向得分匹配 队列 队列研究 肺 肿瘤科 癌症 性能状态 不利影响 呼吸道疾病 胸膜成形术 生存分析 胸膜疾病
作者
Chang Qi,Yalun Li,Ran Wang,Yi Xiang,Hailong Wei,Yong Cao,Ling Peng,Changyi Li,宋慧芳,Hui Ren,Li Jiang,Ran Li,Jia Zeng,Minjiang Chen,Dehe Chen,Yi Zeng,Xueling Wu,Qinghua Liu,Yi Zhang,Huai Liao
出处
期刊:Therapeutic Advances in Respiratory Disease [SAGE Publishing]
卷期号:20: 17534666261499218-17534666261499218
标识
DOI:10.1177/17534666261499218
摘要

Background Intrapleural anticancer therapies are increasingly used in clinical practice; however, their additional benefit over indwelling pleural catheter (IPC) alone and the optimal intrapleural strategy remain uncertain. Platinum-based chemotherapy is a common intrapleural approach. Objective This study evaluated the efficacy and safety of IPC combined with intrapleural platinum-based chemotherapy in lung cancer patients with symptomatic malignant pleural effusion (MPE). Design A multicenter retrospective real-world cohort study. Methods Patients with symptomatic MPE from 27 tertiary care centers received IPC alone, IPC combined with intrapleural platinum-based chemotherapy, or IPC combined with other intrapleural agents. The primary endpoint was progression-free survival of MPE (MPE PFS); secondary endpoints were overall survival (OS), the objective response rate of MPE at 8 weeks (8-week MPE ORR), and safety. Propensity score matching (PSM) was performed as a sensitivity analysis. Results Of the 391 patients, 229 received IPC alone, 93 received IPC combined with intrapleural platinum-based chemotherapy, and 69 received other intrapleural agents. Among the evaluated strategies, platinum-based chemotherapy was associated with the longest MPE PFS and the highest 8-week MPE ORR (87.1%). Compared with IPC alone, the hazard ratios (HRs) for MPE PFS and OS were 0.64 (95% confidence interval [CI], 0.46 -0.88; P = 0.006) and 0.69 (95% CI, 0.50 -0.97; P = 0.035), respectively. Multivariate Cox regression analysis identified intrapleural platinum-based chemotherapy as an independent predictor of prolonged MPE PFS, but not OS. The associations with MPE PFS and 8-week MPE ORR findings remained significant after PSM, whereas OS did not differ. Within the platinum-based chemotherapy group, regimens that included antiangiogenesis or interleukin-2 did not confer additional benefit over platinum monotherapy. Adverse event rates were comparable between groups (11.3% vs. 17.2%; P = 0.219). Conclusions IPC combined with intrapleural platinum-based chemotherapy was associated with improved pleural control and acceptable safety.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
杰星发布了新的文献求助10
1秒前
Kuko完成签到,获得积分10
2秒前
俞治丞发布了新的文献求助10
2秒前
like完成签到 ,获得积分10
2秒前
何钦发布了新的文献求助10
3秒前
歪歪发布了新的文献求助10
3秒前
5秒前
7秒前
8秒前
Ava的应助被转基因哈士奇采纳,获得10
11秒前
sun完成签到 ,获得积分10
12秒前
柔弱的御姐完成签到,获得积分10
13秒前
所所的应助被取个昵称不容易采纳,获得20
14秒前
14秒前
xiaomaihua发布了新的文献求助10
14秒前
14秒前
我是老大的应助被hmx采纳,获得10
14秒前
15秒前
15秒前
英姑的应助被杰星采纳,获得10
16秒前
wuliaodexiaolai完成签到,获得积分20
16秒前
17秒前
17秒前
xc发布了新的文献求助10
18秒前
18秒前
ty发布了新的文献求助10
20秒前
20秒前
20秒前
xc发布了新的文献求助10
21秒前
xc发布了新的文献求助10
21秒前
xc发布了新的文献求助10
21秒前
hd完成签到,获得积分10
22秒前
22秒前
初景发布了新的文献求助10
23秒前
23秒前
大个的应助被pu萄采纳,获得10
24秒前
Yao发布了新的文献求助10
25秒前
25秒前
25秒前
慕青的应助被DearWhite采纳,获得10
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189722
求助须知:如何正确求助?哪些是违规求助? 9576968
关于积分的说明 21850614
捐赠科研通 7787686
什么是DOI,文献DOI怎么找? 3435771
关于科研通互助平台的介绍 2559813
邀请新用户注册赠送积分活动 2482639